CN107208125A - 错折叠蛋白质的检测 - Google Patents
错折叠蛋白质的检测 Download PDFInfo
- Publication number
- CN107208125A CN107208125A CN201580058606.3A CN201580058606A CN107208125A CN 107208125 A CN107208125 A CN 107208125A CN 201580058606 A CN201580058606 A CN 201580058606A CN 107208125 A CN107208125 A CN 107208125A
- Authority
- CN
- China
- Prior art keywords
- misfolded proteins
- soluble
- proteins matter
- sample
- incubated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 629
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 628
- 238000001514 detection method Methods 0.000 title claims description 41
- 238000000034 method Methods 0.000 claims abstract description 218
- 239000000203 mixture Substances 0.000 claims abstract description 150
- 238000011534 incubation Methods 0.000 claims abstract description 126
- 230000002776 aggregation Effects 0.000 claims abstract description 86
- 238000004220 aggregation Methods 0.000 claims abstract description 86
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 35
- 108091000054 Prion Proteins 0.000 claims abstract description 31
- 102000029797 Prion Human genes 0.000 claims abstract description 10
- 239000000523 sample Substances 0.000 claims description 213
- 239000000178 monomer Substances 0.000 claims description 83
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 62
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 claims description 48
- 238000002560 therapeutic procedure Methods 0.000 claims description 36
- 230000003321 amplification Effects 0.000 claims description 35
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 35
- 210000002381 plasma Anatomy 0.000 claims description 29
- 238000002965 ELISA Methods 0.000 claims description 28
- 239000000872 buffer Substances 0.000 claims description 25
- 238000001262 western blot Methods 0.000 claims description 21
- 238000013019 agitation Methods 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 239000011324 bead Substances 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 239000007790 solid phase Substances 0.000 claims description 17
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 15
- -1 TZDM Chemical compound 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 230000004044 response Effects 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 claims description 9
- 206010002022 amyloidosis Diseases 0.000 claims description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 8
- 230000000052 comparative effect Effects 0.000 claims description 8
- 239000013068 control sample Substances 0.000 claims description 8
- 238000000151 deposition Methods 0.000 claims description 8
- 230000004962 physiological condition Effects 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 7
- 108091005804 Peptidases Proteins 0.000 claims description 7
- 239000004365 Protease Substances 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 7
- 238000001493 electron microscopy Methods 0.000 claims description 7
- 206010050337 Cerumen impaction Diseases 0.000 claims description 6
- 210000004381 amniotic fluid Anatomy 0.000 claims description 6
- 210000003567 ascitic fluid Anatomy 0.000 claims description 6
- 210000000941 bile Anatomy 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 6
- 210000002939 cerumen Anatomy 0.000 claims description 6
- 210000003608 fece Anatomy 0.000 claims description 6
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims description 6
- 210000002751 lymph Anatomy 0.000 claims description 6
- 210000004080 milk Anatomy 0.000 claims description 6
- 239000008267 milk Substances 0.000 claims description 6
- 235000013336 milk Nutrition 0.000 claims description 6
- 210000003296 saliva Anatomy 0.000 claims description 6
- 210000002374 sebum Anatomy 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 210000004243 sweat Anatomy 0.000 claims description 6
- 210000002700 urine Anatomy 0.000 claims description 6
- IAVCEBMLYVGBLA-UHFFFAOYSA-N 2-[1-[6-[2-fluoroethyl(methyl)amino]naphthalen-2-yl]ethylidene]propanedinitrile Chemical compound C1=C(C(C)=C(C#N)C#N)C=CC2=CC(N(CCF)C)=CC=C21 IAVCEBMLYVGBLA-UHFFFAOYSA-N 0.000 claims description 5
- KLFRZDOQQDHVSS-UHFFFAOYSA-N 2-[[5-[5-(4-hydroxyphenyl)thiophen-2-yl]thiophen-2-yl]methylidene]propanedinitrile Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=2SC(C=C(C#N)C#N)=CC=2)S1 KLFRZDOQQDHVSS-UHFFFAOYSA-N 0.000 claims description 5
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 5
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 5
- 102000011931 Nucleoproteins Human genes 0.000 claims description 5
- 108010061100 Nucleoproteins Proteins 0.000 claims description 5
- XFFSCOOTVXBLCK-QAVVBOBSSA-N OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)-c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O Chemical compound OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)-c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O XFFSCOOTVXBLCK-QAVVBOBSSA-N 0.000 claims description 5
- 208000002151 Pleural effusion Diseases 0.000 claims description 5
- 238000004630 atomic force microscopy Methods 0.000 claims description 5
- KPMVHELZNRNSMN-UHFFFAOYSA-N chembl1985849 Chemical compound N1=CC=C2NCCN21 KPMVHELZNRNSMN-UHFFFAOYSA-N 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 210000004051 gastric juice Anatomy 0.000 claims description 5
- 229920000123 polythiophene Polymers 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 230000002285 radioactive effect Effects 0.000 claims description 5
- 238000004611 spectroscopical analysis Methods 0.000 claims description 5
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 claims description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 4
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 claims description 4
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 claims description 4
- 239000007992 BES buffer Substances 0.000 claims description 4
- 241000283707 Capra Species 0.000 claims description 4
- 241000282326 Felis catus Species 0.000 claims description 4
- 239000007995 HEPES buffer Substances 0.000 claims description 4
- 239000007987 MES buffer Substances 0.000 claims description 4
- 239000007993 MOPS buffer Substances 0.000 claims description 4
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 claims description 4
- 239000007990 PIPES buffer Substances 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 239000007994 TES buffer Substances 0.000 claims description 4
- 210000004400 mucous membrane Anatomy 0.000 claims description 4
- 239000002953 phosphate buffered saline Substances 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 241000282979 Alces alces Species 0.000 claims description 3
- 241000282994 Cervidae Species 0.000 claims description 3
- 241000283073 Equus caballus Species 0.000 claims description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 claims description 3
- 238000005481 NMR spectroscopy Methods 0.000 claims description 3
- 238000005251 capillar electrophoresis Methods 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 238000000804 electron spin resonance spectroscopy Methods 0.000 claims description 3
- 238000003384 imaging method Methods 0.000 claims description 3
- 238000003118 sandwich ELISA Methods 0.000 claims description 3
- 230000003595 spectral effect Effects 0.000 claims description 3
- 238000000870 ultraviolet spectroscopy Methods 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 230000010355 oscillation Effects 0.000 claims description 2
- 108020005087 unfolded proteins Proteins 0.000 claims 13
- 206010061592 cardiac fibrillation Diseases 0.000 claims 6
- 239000002131 composite material Substances 0.000 claims 6
- 230000002600 fibrillogenic effect Effects 0.000 claims 6
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 claims 6
- 206010008748 Chorea Diseases 0.000 claims 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000012491 analyte Substances 0.000 claims 3
- 239000012620 biological material Substances 0.000 claims 3
- 210000003097 mucus Anatomy 0.000 claims 3
- 208000033510 neuroaxonal dystrophy Diseases 0.000 claims 3
- 235000021286 stilbenes Nutrition 0.000 claims 3
- 238000003756 stirring Methods 0.000 claims 3
- 210000000225 synapse Anatomy 0.000 claims 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims 2
- 102000002322 Egg Proteins Human genes 0.000 claims 2
- 108010000912 Egg Proteins Proteins 0.000 claims 2
- 241000282898 Sus scrofa Species 0.000 claims 2
- 238000005100 correlation spectroscopy Methods 0.000 claims 2
- 235000014103 egg white Nutrition 0.000 claims 2
- 210000000969 egg white Anatomy 0.000 claims 2
- 235000013601 eggs Nutrition 0.000 claims 2
- 238000010348 incorporation Methods 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 238000001228 spectrum Methods 0.000 claims 2
- 210000004885 white matter Anatomy 0.000 claims 2
- 230000001900 immune effect Effects 0.000 claims 1
- 238000007689 inspection Methods 0.000 claims 1
- 210000003281 pleural cavity Anatomy 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 65
- 102000001708 Protein Isoforms Human genes 0.000 abstract description 24
- 108010029485 Protein Isoforms Proteins 0.000 abstract description 24
- 102000003802 alpha-Synuclein Human genes 0.000 description 39
- 108090000185 alpha-Synuclein Proteins 0.000 description 39
- 208000007153 proteostasis deficiencies Diseases 0.000 description 34
- 230000004770 neurodegeneration Effects 0.000 description 30
- 208000015122 neurodegenerative disease Diseases 0.000 description 29
- 102100034452 Alternative prion protein Human genes 0.000 description 22
- 238000003556 assay Methods 0.000 description 22
- 230000035945 sensitivity Effects 0.000 description 18
- 108010026424 tau Proteins Proteins 0.000 description 17
- 102000013498 tau Proteins Human genes 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 230000003941 amyloidogenesis Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 11
- 239000013610 patient sample Substances 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 238000003318 immunodepletion Methods 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 102000009027 Albumins Human genes 0.000 description 9
- 108010088751 Albumins Proteins 0.000 description 9
- 208000024777 Prion disease Diseases 0.000 description 9
- 125000004122 cyclic group Chemical group 0.000 description 9
- 230000013632 homeostatic process Effects 0.000 description 9
- 238000010899 nucleation Methods 0.000 description 9
- 230000006933 amyloid-beta aggregation Effects 0.000 description 8
- 102000003799 beta-Synuclein Human genes 0.000 description 8
- 108090000182 beta-Synuclein Proteins 0.000 description 8
- 238000001114 immunoprecipitation Methods 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 238000000527 sonication Methods 0.000 description 8
- 206010012289 Dementia Diseases 0.000 description 7
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 7
- 239000013060 biological fluid Substances 0.000 description 7
- 230000001747 exhibiting effect Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000005284 excitation Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000006384 oligomerization reaction Methods 0.000 description 6
- 238000010532 solid phase synthesis reaction Methods 0.000 description 6
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 5
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 5
- 208000023105 Huntington disease Diseases 0.000 description 5
- 102000019355 Synuclein Human genes 0.000 description 5
- 108050006783 Synuclein Proteins 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000010544 human prion disease Diseases 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 4
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 4
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 102000007562 Serum Albumin Human genes 0.000 description 4
- 108010071390 Serum Albumin Proteins 0.000 description 4
- 208000032859 Synucleinopathies Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 238000001215 fluorescent labelling Methods 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 201000002832 Lewy body dementia Diseases 0.000 description 3
- 239000006137 Luria-Bertani broth Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000011979 disease modifying therapy Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000009593 lumbar puncture Methods 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000002850 nasal mucosa Anatomy 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 230000003557 neuropsychological effect Effects 0.000 description 3
- 230000001151 other effect Effects 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 238000010149 post-hoc-test Methods 0.000 description 3
- 208000022256 primary systemic amyloidosis Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000001179 synovial fluid Anatomy 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 238000004879 turbidimetry Methods 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 102400000573 Amyloid-beta protein 40 Human genes 0.000 description 2
- 102400000574 Amyloid-beta protein 42 Human genes 0.000 description 2
- 102100021257 Beta-secretase 1 Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 2
- 101710115937 Microtubule-associated protein tau Proteins 0.000 description 2
- 241000282943 Odocoileus Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- FEWOUVRMGWFWIH-ILZZQXMPSA-N amyloid-beta polypeptide 40 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 FEWOUVRMGWFWIH-ILZZQXMPSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 238000013211 curve analysis Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 208000037957 feline spongiform encephalopathy Diseases 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 238000003312 immunocapture Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003961 neuronal insult Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 230000007111 proteostasis Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000012421 spiking Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 208000037956 transmissible mink encephalopathy Diseases 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- PKXWXXPNHIWQHW-RCBQFDQVSA-N (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound C1CN(C)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](O)C(C)C)C2=CC=CC=C21 PKXWXXPNHIWQHW-RCBQFDQVSA-N 0.000 description 1
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 108010094108 Amyloid Proteins 0.000 description 1
- 102000001049 Amyloid Human genes 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- XEAOPVUAMONVLA-QGZVFWFLSA-N Avagacestat Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N([C@H](CCC(F)(F)F)C(=O)N)CC(C(=C1)F)=CC=C1C=1N=CON=1 XEAOPVUAMONVLA-QGZVFWFLSA-N 0.000 description 1
- 101710150192 Beta-secretase 1 Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- WKDNQONLGXOZRG-HRNNMHKYSA-N CO[C@H]1CC[C@@]2(Cc3ccc(cc3[C@@]22N=C(C)C(N)=N2)-c2cncc(c2)C#CC)CC1 Chemical compound CO[C@H]1CC[C@@]2(Cc3ccc(cc3[C@@]22N=C(C)C(N)=N2)-c2cncc(c2)C#CC)CC1 WKDNQONLGXOZRG-HRNNMHKYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 241000282985 Cervus Species 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- 102000001477 Deubiquitinating Enzymes Human genes 0.000 description 1
- 108010093668 Deubiquitinating Enzymes Proteins 0.000 description 1
- 101150097070 Drd3 gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 1
- 101000867817 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1D Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 208000035177 MELAS Diseases 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 241000933101 Tragelaphus scriptus Species 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000007792 alzheimer disease pathology Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- 229950001863 bapineuzumab Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000017580 chronic wasting disease Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229950001954 crenezumab Drugs 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000002060 fluorescence correlation spectroscopy Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 102000004963 gamma-Synuclein Human genes 0.000 description 1
- 108090001121 gamma-Synuclein Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000007121 neuropathological change Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000003077 normal pressure hydrocephalus Diseases 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002776 polycyclohexyl methacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229950007874 solanezumab Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 108010084171 vanutide cridificar Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049306P | 2014-09-11 | 2014-09-11 | |
| US62/049,306 | 2014-09-11 | ||
| PCT/US2015/049844 WO2016040907A1 (en) | 2014-09-11 | 2015-09-11 | Detection of misfolded proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107208125A true CN107208125A (zh) | 2017-09-26 |
Family
ID=55454515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580058606.3A Pending CN107208125A (zh) | 2014-09-11 | 2015-09-11 | 错折叠蛋白质的检测 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20160077112A1 (enExample) |
| EP (2) | EP3191599B1 (enExample) |
| JP (2) | JP6980953B2 (enExample) |
| KR (1) | KR102448128B1 (enExample) |
| CN (1) | CN107208125A (enExample) |
| AU (1) | AU2015314783B2 (enExample) |
| BR (1) | BR112017004899A2 (enExample) |
| CA (1) | CA2960830C (enExample) |
| ES (1) | ES2953855T3 (enExample) |
| HR (1) | HRP20231232T1 (enExample) |
| IL (2) | IL251052B (enExample) |
| MX (1) | MX2017003269A (enExample) |
| PL (1) | PL3191599T3 (enExample) |
| SG (2) | SG10202008464UA (enExample) |
| WO (1) | WO2016040907A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108088816A (zh) * | 2018-01-23 | 2018-05-29 | 深圳市国赛生物技术有限公司 | 小型特定蛋白分析仪 |
| CN114199875A (zh) * | 2022-02-18 | 2022-03-18 | 之江实验室 | 一种蛋白质多聚体是否可作为力缓冲剂的判断方法及装置 |
| CN115003824A (zh) * | 2019-09-04 | 2022-09-02 | 安培里翁公司 | 使用珠子检测α-突触核蛋白 |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10989718B2 (en) | 2014-09-11 | 2021-04-27 | Amprion, Inc. | Detection of misfolded alpha synuclein protein |
| GB201611840D0 (en) * | 2016-07-07 | 2016-08-24 | Univ Court Of The Univ Of Edinburgh The | Alpha-synuclein detection assay |
| EP3583124A1 (en) | 2017-02-17 | 2019-12-25 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| TW201901153A (zh) * | 2017-05-16 | 2019-01-01 | 美商安培恩股份有限公司 | 折疊錯誤之ｔａｕ蛋白的檢測及檢測折疊錯誤之ｔａｕ蛋白的套組 |
| EP3692373A1 (en) * | 2017-10-02 | 2020-08-12 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Assay for the detection of alpha-synuclein seeding activity associated with synucleinopathies |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| EP3729088B1 (en) * | 2017-12-21 | 2021-10-20 | H. Lundbeck A/S | Diagnosis and treatment of alpha-synucleinopathies |
| GB201803553D0 (en) | 2018-03-06 | 2018-04-18 | Univ Newcastle | Detection of pathological protein aggregation |
| WO2019222554A2 (en) * | 2018-05-16 | 2019-11-21 | Amprion, Inc. | Detection of brain injury or neurological disease using tau protein |
| JP7125544B2 (ja) | 2018-09-21 | 2022-08-24 | ディープマインド テクノロジーズ リミテッド | 品質スコアの勾配を使用した反復的なタンパク質構造予測 |
| JP7376040B2 (ja) * | 2019-09-03 | 2023-11-08 | 国立大学法人京都工芸繊維大学 | 神経変性疾患におけるバイオマーカー分子の検出方法 |
| KR102277871B1 (ko) * | 2019-12-17 | 2021-07-15 | 원광대학교산학협력단 | 소변의 알파-씨누클레인 중합체 측정에 의한 파킨슨병 진단 정보의 수집방법 및 그 키트 |
| WO2021198098A1 (en) | 2020-04-03 | 2021-10-07 | Universität Zürich | Improved method of detecting biomarkers in a biological sample |
| IL298225A (en) * | 2020-05-18 | 2023-01-01 | Amprion Inc | Alpha-synuclein substrates and methods for making and using the same |
| WO2022105923A1 (zh) * | 2020-11-21 | 2022-05-27 | 浙江数问生物技术有限公司 | 用于检测生物样本中的错误折叠蛋白质的装置和方法 |
| US20240192230A1 (en) * | 2021-04-15 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Digital Protein Misfolding Assays |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101156068A (zh) * | 2005-02-15 | 2008-04-02 | 阿德利夫股份有限公司 | 检测错折叠蛋白和朊病毒的方法 |
| US20080118938A1 (en) * | 2006-09-06 | 2008-05-22 | Lisbell Estrada | Methods and Compositions for the Detection of Protein Folding Disorders |
| CN101421304A (zh) * | 2006-02-16 | 2009-04-29 | 克劳斯贝塔生物科学有限公司 | 亲和区 |
| CN101454335A (zh) * | 2006-05-19 | 2009-06-10 | 斯克里普斯研究所 | 蛋白质错折叠的治疗 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ523213A (en) | 2000-07-07 | 2005-01-28 | Applied Research Systems | Early diagnosis of conformational diseases |
| WO2002054083A2 (en) * | 2001-01-03 | 2002-07-11 | Ortho-Mcneil Pharmaceutical, Inc. | Alpha synuclein aggregation assays |
| GB0203446D0 (en) * | 2002-02-14 | 2002-04-03 | Univ Lancaster | Detection and/or monitoring of synuclein-related diseases |
| JP2010043865A (ja) * | 2006-12-12 | 2010-02-25 | Olympus Corp | 異常型プリオンの検出方法 |
| CN102666577A (zh) * | 2009-11-24 | 2012-09-12 | 前体生物药物股份公司 | 诊断阿尔茨海默病或轻度认知损害的新的诊断方法 |
| US9133343B2 (en) * | 2009-11-30 | 2015-09-15 | Enzo Biochem, Inc. | Dyes and compositions, and processes for using same in analysis of protein aggregation and other applications |
| US9910049B2 (en) * | 2014-09-11 | 2018-03-06 | Amprion, Inc. | Detection of misfolded amyloid beta protein |
| AU2012207454B2 (en) * | 2011-01-18 | 2016-11-17 | Prionics Ag | Methods for amplification and detection of prions |
| US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
-
2015
- 2015-09-11 US US14/852,478 patent/US20160077112A1/en not_active Abandoned
- 2015-09-11 EP EP15839278.7A patent/EP3191599B1/en active Active
- 2015-09-11 CN CN201580058606.3A patent/CN107208125A/zh active Pending
- 2015-09-11 EP EP23189057.5A patent/EP4292654A3/en active Pending
- 2015-09-11 JP JP2017533721A patent/JP6980953B2/ja active Active
- 2015-09-11 HR HRP20231232TT patent/HRP20231232T1/hr unknown
- 2015-09-11 ES ES15839278T patent/ES2953855T3/es active Active
- 2015-09-11 MX MX2017003269A patent/MX2017003269A/es unknown
- 2015-09-11 WO PCT/US2015/049844 patent/WO2016040907A1/en not_active Ceased
- 2015-09-11 SG SG10202008464UA patent/SG10202008464UA/en unknown
- 2015-09-11 BR BR112017004899A patent/BR112017004899A2/pt active Search and Examination
- 2015-09-11 SG SG11201701953RA patent/SG11201701953RA/en unknown
- 2015-09-11 AU AU2015314783A patent/AU2015314783B2/en active Active
- 2015-09-11 KR KR1020177009707A patent/KR102448128B1/ko active Active
- 2015-09-11 CA CA2960830A patent/CA2960830C/en active Active
- 2015-09-11 PL PL15839278.7T patent/PL3191599T3/pl unknown
-
2017
- 2017-03-09 IL IL251052A patent/IL251052B/en unknown
-
2021
- 2021-05-12 JP JP2021081274A patent/JP7104943B2/ja active Active
-
2022
- 2022-03-30 IL IL291809A patent/IL291809B2/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101156068A (zh) * | 2005-02-15 | 2008-04-02 | 阿德利夫股份有限公司 | 检测错折叠蛋白和朊病毒的方法 |
| CN101421304A (zh) * | 2006-02-16 | 2009-04-29 | 克劳斯贝塔生物科学有限公司 | 亲和区 |
| CN101454335A (zh) * | 2006-05-19 | 2009-06-10 | 斯克里普斯研究所 | 蛋白质错折叠的治疗 |
| US20080118938A1 (en) * | 2006-09-06 | 2008-05-22 | Lisbell Estrada | Methods and Compositions for the Detection of Protein Folding Disorders |
Non-Patent Citations (3)
| Title |
|---|
| MARIA EUGENIA HERVA ET AL.: "Anti-amyloid Compounds Inhibit α-Synuclein Aggregation Induced by Protein Misfolding Cyclic Amplification (PMCA)", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 * |
| NATALIA SALVADORES ET AL.: "Detection of Misfolded Aβ Oligomers for Sensitive Biochemical Diagnosis of Alzheimer’s Disease", 《CELL REPORTS》 * |
| 陈明辉 等: "错误折叠蛋白质的聚集效应及其对策", 《生命的化学》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108088816A (zh) * | 2018-01-23 | 2018-05-29 | 深圳市国赛生物技术有限公司 | 小型特定蛋白分析仪 |
| CN115003824A (zh) * | 2019-09-04 | 2022-09-02 | 安培里翁公司 | 使用珠子检测α-突触核蛋白 |
| CN114199875A (zh) * | 2022-02-18 | 2022-03-18 | 之江实验室 | 一种蛋白质多聚体是否可作为力缓冲剂的判断方法及装置 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2960830A1 (en) | 2016-03-17 |
| EP3191599A4 (en) | 2018-03-14 |
| EP3191599C0 (en) | 2023-08-02 |
| IL291809A (en) | 2022-06-01 |
| JP6980953B2 (ja) | 2021-12-15 |
| WO2016040907A1 (en) | 2016-03-17 |
| ES2953855T3 (es) | 2023-11-16 |
| KR102448128B1 (ko) | 2022-09-27 |
| US20160077112A1 (en) | 2016-03-17 |
| HRP20231232T1 (hr) | 2024-01-19 |
| EP3191599B1 (en) | 2023-08-02 |
| IL251052B (en) | 2022-05-01 |
| EP3191599A1 (en) | 2017-07-19 |
| JP2022000629A (ja) | 2022-01-04 |
| CA2960830C (en) | 2023-09-05 |
| MX2017003269A (es) | 2017-12-04 |
| SG11201701953RA (en) | 2017-04-27 |
| JP2017530373A (ja) | 2017-10-12 |
| SG10202008464UA (en) | 2020-10-29 |
| KR20170103741A (ko) | 2017-09-13 |
| AU2015314783B2 (en) | 2021-10-21 |
| PL3191599T3 (pl) | 2023-12-27 |
| BR112017004899A2 (pt) | 2017-12-12 |
| EP4292654A2 (en) | 2023-12-20 |
| IL251052A0 (en) | 2017-04-30 |
| IL291809B2 (en) | 2023-06-01 |
| JP7104943B2 (ja) | 2022-07-22 |
| EP4292654A3 (en) | 2024-01-03 |
| AU2015314783A1 (en) | 2017-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7104943B2 (ja) | ミスフォールディングタンパク質の検出 | |
| US20240219406A1 (en) | Detection of misfolded alpha synuclein protein | |
| US9910049B2 (en) | Detection of misfolded amyloid beta protein | |
| US20220137073A1 (en) | Detection of misfolded tau protein | |
| US20210102961A1 (en) | Detection of misfolded proteins | |
| HK40105178A (en) | Detection of misfolded proteins | |
| US20190137515A1 (en) | Methods for estimating misfolded protein concentration in fluids and tissue by quantitative pmca | |
| US20190353669A1 (en) | Detection of Brain Injury or Neurological Disease using Tau Protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |